10 Results

People

  1. Zelenetz
    Zelenetz
  2. Noy
    Noy
  3. Salles
    Salles
  4. Stuver
    Stuver
  5. Batlevi
    Batlevi
  6. Moskowitz
    Moskowitz
  7. Seshan
    Seshan
  8. Vardhana
    Vardhana
  9. Falchi
    Falchi
  10. Lahoud
    Lahoud

Groups

  1. Center for Hematologic Malignancies (10)
  2. Department of Medicine (10)
  3. GME, Medicine (10)
  4. Graduate Medical Education (10)
  5. Hematologic Malignancies, Division of (10)
  6. Lymphoma (10)
  7. Hematology-Oncology Fellows (5)
  8. Biostatistics Service (4)
  9. Epidemiology and Biostatistics (4)
  10. Survivorship Research (4)
  1. "Center for Hematologic Malignancies"
  2. "GME, Medicine"
  3. "Lymphoma"
  4. "Research letter"
Formats
  1. Research Letter (10)
Groups
  1. Center for Hematologic Malignancies (10)
  2. Department of Medicine (10)
  3. GME, Medicine (10)
  4. Graduate Medical Education (10)
  5. Hematologic Malignancies, Division of (10)
  6. Lymphoma (10)

More Groups

People
  1. Andrew Zelenetz (6)
  2. Ariela Noy (5)
  3. Gilles Salles (4)
  4. Robert Stuver (4)
  5. Alison Moskowitz (3)
  6. Anthony Mato (3)

More People

Years
  1. 2024 (2)
  2. 2023 (5)
  3. 2022 (2)
  4. 2020 (1)
Publications
  1. Leukemia and Lymphoma (3)
  2. British Journal of Haematology (2)
  3. American Journal of Hematology (1)
  4. Blood (1)
  5. Blood Advances (1)
  6. Cancer Cell (1)

More Publications

Publishers
  1. John Wiley & Sons (3)
  2. Taylor & Francis Group (3)
  3. American Society of Hematology (2)
  4. Cell Press (1)
  5. Nature Publishing Group (1)

Results (10)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • BEAM versus pharmacokinetics-directed BuCyVP16 conditioning for patients with peripheral T-cell lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation
    Research Letter

    Stuver, R.; Mian, A.; Brown, S.; Devlin, S.; Caimi, P. F.; Chinapen, S.; Dahi, P.; Dean, R.; Epstein-Peterson, Z. D.; Hill, B.; more...
    American Journal of Hematology (2024)

    Fulltext@MSK | Save
  • Gemcitabine plus pembrolizumab after checkpoint blockade failure as a strategy in multiply relapsed Hodgkin lymphoma
    Research Letter

    Stuver, R.; Noy, A.; Vardhana, S. A.; Zelenetz, A. D.; Moskowitz, A. J.
    British Journal of Haematology (2024)

    Fulltext@MSK | Save
  • Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study
    Research Letter

    Qualls, D. A.; Lambert, N.; Caimi, P. F.; Merrill, M.; Pullarkat, P.; Godby, R. C.; Bond, D. A.; Wehmeyer, G. T.; Romancik, J.; Amoozgar, B.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Disease response upon cessation of methotrexate in a patient with Hodgkin lymphoma treated with pembrolizumab
    Research Letter

    Stuver, R.; Vardhana, S. A.; Bedmutha, A.; Chan, K. K.; Mirtcheva-Trocheva, R.; Nosov, A.; Schöder, H.; Moskowitz, A.
    Leukemia and Lymphoma (2023)

    Fulltext@MSK | Save
  • The efficacy of tixagevimab–cilgavimab prophylaxis against Omicron BA.5 variants in patients with hematological malignancies: Insights from the Leukemia and Lymphoma Society Registry
    Research Letter

    Luttwak, E.; Noy, A.; Seshan, V.; Saltzman, L. A.; Greenberger, L. M.
    Leukemia and Lymphoma (2023)

    Fulltext@MSK | Save
  • Molecularly targeted epigenetic therapy with mocetinostat in relapsed and refractory non-Hodgkin lymphoma with CREBBP or EP300 mutations: An open label phase II study
    Research Letter

    Qualls, D.; Noy, A.; Straus, D.; Matasar, M.; Moskowitz, C.; Seshan, V.; Dogan, A.; Salles, G.; Younes, A.; Zelenetz, A. D.; more...
    Leukemia and Lymphoma (2023)

    Fulltext@MSK | Save
  • Long-term outcomes of patients with limited-stage ocular adnexal DLBCL treated with combined modality therapy in the rituximab era
    Research Letter

    Qualls, D.; Imber, B. S.; Okwali, M.; Hamlin, P. A.; Kumar, A.; Lahoud, O. B.; Matasar, M. J.; Noy, A.; Owens, C.; Zelenetz, A. D.; more...
    British Journal of Haematology (2023)

    Fulltext@MSK | Save
  • Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen
    Research Letter

    Thompson, M. C.; Harrup, R. A.; Coombs, C. C.; Roeker, L. E.; Pu, J. J.; Choi, M. Y.; Barr, P. M.; Allan, J. N.; Šimkovič, M.; Leslie, L.; more...
    Blood Advances (2022)

    Fulltext@MSK | Save
  • Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies
    Research Letter

    Stuver, R.; Shah, G. L.; Korde, N. S.; Roeker, L. E.; Mato, A. R.; Batlevi, C. L.; Chung, D. J.; Doddi, S.; Falchi, L.; Gyurkocza, B.; more...
    Cancer Cell (2022)

    Fulltext@MSK | Save
  • Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia
    Research Letter

    Roeker, L. E.; Knorr, D. A.; Pessin, M. S.; Ramanathan, L. V.; Thompson, M. C.; Leslie, L. A.; Zelenetz, A. D.; Mato, A. R.
    Leukemia (2020)

    Fulltext@MSK | Save